Death or Neurodevelopmental Impairment at 18 To 22 Months in a Randomized Trial of Early Dexamethasone to Prevent Death or Chronic Lung Disease in Extremely Low Birth Weight Infants

OBJECTIVE: To evaluate the incidence of death or neurodevelopmental impairment (NDI) at 18 to 22 months corrected age in subjects enrolled in a trial of early dexamethasone treatment to prevent death or chronic lung disease in extremely low birth weight infants. METHODS: Evaluation of infants at 18...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Stark, Ann R., Carlo, Waldemar A., Vohr, Betty R, Papile, Lu Ann, Saha, Shampa, Bauer, Charles R., Donovan, Edward F., Oh, William, Shankaran, Seetha, Tyson, Jon E., Wright, Linda L., Poole, W. Kenneth, Das, Abhik, Stoll, Barbara J., Fanaroff, Avroy A., Korones, Sheldon B., Ehrenkranz, Richard A., Stevenson, David K., Peralta-Carcelen, Myriam, Adams-Chapman, Ira, Wilson-Costello, Deanne E., Bada, Henrietta S., Heyne, Roy J., Johnson, Yvette R., Lee, Kimberly Gronsman, Steichen, Jean J., Hintz, Susan R.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4120744/
https://ncbi.nlm.nih.gov/pubmed/23992673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpeds.2013.07.027
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares